Rationale: Endothelial progenitor cell (EPC) survival and function in the injured myocardium is adversely influenced by hostile microenvironment such as ischemia, hypoxia, and inflammatory response, thereby compromising full benefits of EPC-mediated myocardial repair.
S everal strategies to modify and enhance stem cellmediated ischemic myocardial repair and regeneration have shown promising results. [1] [2] [3] [4] [5] [6] [7] [8] [9] Increasing evidence from animal models of experimental ischemic injuries suggest that endothelial progenitor cells (EPC) participate in the process of neovascularization and tissue repair leading to enhanced recovery of ischemic myocardium. 10 -13 Furthermore, clinical trials involving bone marrow-derived EPC transplantation for ischemic myocardium have confirmed this possibility. 14 -18 However, the adverse effects of ischemic tissue (hostile microenvironment) such as inflammation and hypoxia on the survival and function of the mobilized/transplanted EPC during angiogenesis/vasculogenesis and tissue repair is still a poses a challenge and research on the means to enhance stem cell survival, and function is limited. Heart failure patients with high circulating levels of TNF-␣, a potent proinflammatory cytokine, were associated with significantly lower EPC counts as compared with patients treated with TNF-␣ blocker. 19 Most importantly, these EPCs exposed to prolonged inflammatory stimulus may be functionally impaired. 20 Survival of EPCs after their intramyocardial transplantation is a strong indicator of favorable cardiovascular prognosis in cell-based therapy. 21 These studies suggest that ischemic microenvironment including adverse inflammatory response has a deleterious effect on EPC survival and function. Therefore, modulation of local tissue microenvironment by anti-inflammatory factors either released by stem cells or through systemic delivery is important in conferring improved outcome after stem cell therapy. Previous studies from our laboratory and others [22] [23] [24] [25] have shown that administration of interleukin (IL)-10, a potent anti-inflammatory cytokine, significantly improved after acute myocardial infarction (MI) left ventricular (LV) functions, reduced cardiomyocyte apoptosis and fibrosis, and enhanced neovascularization in the ischemic border zone. Interestingly, whether attenuating the proinflammatory response on EPC biology can maximize the benefits of EPC-mediated myocardial repair in particular and cardiovascular events in general have not been explored yet. Therefore, we hypothesized that IL-10 modulates EPC biology and enhances its survival and function after transplantation in an ischemic myocardial tissue microenvironment leading to attenuation of MI-induced LV dysfunction and remodeling.
Methods
Comprehensive methods are available as an Online Supplement at http://circres.ahajournals.org.
Results

IL-10 Knockout Mice Display Reduced MI-Induced Mobilization of Bone Marrow-EPC
To determine whether IL-10 affects MI-induced mobilization of bone marrow-EPCs into the circulation, we performed MI and assessed EPC mobilization into the circulation by FACS analysis at 3 days after MI. EPCs were identified as cells coexpressing Sca-1 and Flk-1. Wild-type (WT) mice showed increased number of Flk1ϩ/Sca-1ϩ(doubleϩ) cells at 3 days after MI ( Figure 1A and 1C, PϽ0.05). Interestingly, IL-10 KO mice showed diminished number of circulating EPCs after MI, suggesting that IL-10 deficiency impairs mobilization of EPCs into the circulation in response to myocardial injury ( Figure 1B and 1C, PϽ0.05). Furthermore, we analyzed the number of circulating Sca-1ϩ/CD31ϩ(doubleϩcells) after 3 days after MI. Interestingly, similar trend was observed (Online Figure I, PϽ0.05), suggesting that IL-10 influences mobilization of other progenitor cells of endothelial lineage.
Reconstitution of WT Bone Marrow in IL-10 KO Mice by Bone Marrow Transplantation Attenuates Impaired EPC Mobilization
In an independent experiment, we performed bone marrow transplantation (BMT) followed by MI and assessed EPC mobilization into the circulation by FACS analysis at 3 day after MI. BMT to replace IL-10 KO marrow with WT marrow followed by MI and FACS analysis showed that impaired EPC mobilization in IL-10 KO mice was rescued by the reconstitution of WT BM ( Figure 1C and 1D, PϽ0.05).
Stromal Cell-Derived Factor-1 Administration Reverses Defect in MI-Induced Mobilization in IL-10 KO Mice
Upregulation of stromal cell-derived factor (SDF)-1 in the infarcted hearts causes massive influx of CXCR4-positive stem cells from the bone marrow. 26, 27 We determined the mRNA expression of SDF-1 in the border zone of myocardial infarct after MI by real time-PCR. As illustrated in Figure 1F , SDF-1 mRNA expression significantly increased in the myocardium after MI. Interestingly, MI-induced SDF-1 expression in the myocardium was lower in IL-10 -deficient mice as compared with WT mice at 3 days after MI ( Figure 1F , PϽ0.05). To further demonstrate that MI induced impaired mobilization in IL-10 KO mice is mediated through SDF-1, we injected mouse recombinant SDF-1␣ (500 ng/mouse/d for 3 days; R&D Systems, Minneapolis, MN) through intraperitoneal route after MI to examine if SDF-1 rescues IL-10 phenotype in IL-10 KO mice. FACS analysis was performed for EPC mobilization at 3 days after MI. SDF-1 injection increased MI-induced EPC mobilization as compared with KO mice ( Figure 1C and 1E, PϽ0.05).
IL-10 -Deficient EPC Show Reduced CXCR4 Expression and Are Susceptible to Inflammation or Hypoxia-Induced Apoptosis
Based on the above findings, we first postulated that IL-10 deficiency impairs MI-induced EPC mobilization through SDF1-CXCR4 signaling. To address this issue, we first analyzed CXCR4 expression levels by immunofluorescence staining of cultured EPCs derived from bone marrow of IL-10 WT (WT-EPC) and KO mice (IL-10-deficient; KO-EPC). Cells were treated with lipopolysaccharide (LPS) (to simulate inflammation) or CoCl 2 before the analysis of CXCR4expression. As shown in Figure 2 , CXCR4 expression in response to LPS (dose and time that mimic excessive and prolonged inflammatory stimuli 28, 29 ), was higher in WT-EPC (IL-10ϩ/ϩ) as compared with IL-10 -deficient EPC (KO-EPC) ( Figure 2B ). CoCl 2 -induced hypoxia has similar effects on EPCs (Online Figure II) . CoCl 2 -induced hypoxic state was confirmed by increased HIF-1␣ levels as compared with untreated normoxic cells (Online Figure III) . 
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IL-10 Deficiency Impairs EPC Migration Toward SDF-1 Through CXCR4 Pathway
To first determine the migratory response of ex vivo expanded WT and IL-10 -deficient EPCs toward an SDF-1 gradient, we performed a modified Boyden chamber migration assay ( Figure 3 ). As shown in Figure 3 , migration of both WT and IL-10 -deficient EPCs were enhanced toward SDF-1 gradient (PϽ0.05, Figure 3A , 3B, 3D, 3E, and 3H). However, IL-10 -deficient (KO) EPCs showed significantly lower migration in response to SDF-1 as compared with WT-EPCs (PϽ0.05, Figure 3B , 3E, and 3H). To further investigate if the differential migratory response of ex vivo expanded WT and IL-10 -deficient EPCs toward an SDF-1 gradient are mediated through CXCR4, we incubated EPCs with 10 g/mL AMD3100 (CXCR4 antagonist). Incubation of EPC with the CXCR4 antagonist AMD3100 significantly blocked the increase in SDF-1-induced migration (PϽ0.05, Figure 3C , 3F, and 3H). These data suggest that the impairment in MIinduced BM-EPC mobilization in IL-10 -deficient mice is mediated through SDF-1/CXCR4 signaling axis.
Increased Susceptibility of IL-10 -Deficient EPC to LPS/CoCl 2 -Induced Apoptosis
We evaluated the effect of IL-10 phenotype on the survival of EPCs in response to inflammatory stimuli (LPS) or CoCl 2induced hypoxia, in vitro. EPCs derived from bone marrow of IL-10 WT (WT-EPC) and KO mice (KO-EPC) were incubated on 8-well glass slides coated with 0.1% fibronectin with 50 ng/mL LPS or 100 mol/L CoCl 2 for 24 hours. Apoptosis was assessed using TUNEL staining. LPS-induced apoptosis was significantly higher in IL-10 -deficient EPC as compared with WT-EPCs ( Figure 4A and 4B; PϽ0.01). Similar trends were observed in CoCl 2 treated EPCs (Online Figure IV) .
Systemic IL-10 Therapy Enhances Retention and Survival of Transplanted EPCs in the Ischemic Myocardium
We have previously reported that IL-10 significantly reduced post-MI inflammatory response in the myocardium. 29 We examined the retention and survival of GFPϩEPCs (from Tie2GFP-Tg mice) after their transplantation in the ischemic myocardium (3 days after MI) by assessing the number of GFPϩcells (green) in the myocardium and their apoptosis (red) by TUNEL staining. Nuclei were stained blue with DAPI. As shown in Figure 5A and 5B, mice receiving IL-10 had a higher number of GFPϩEPCs retained in the myocardium as compared with EPCϩsaline group (PϽ0.01). Interestingly, in EPCϩsaline group, a large number of these GFPϩcells were undergoing apoptosis as compared with the mice that received IL-10 ( Figure 5A and 5C; PϽ0.01). These data suggests that IL-10 protects transplanted EPC in the ischemic myocardium and thereby increases the numeric 
IL-10 Therapy Augments EPC-Mediated Neovascularization in the Ischemic Myocardium
To determine the effect of IL-10 on EPC-mediated neovascularization including engraftment of the transplanted EPC into the vascular structures, we assessed capillary density and the number of GFPϩEPC (green) incorporated into the capillaries (red; identified by CD31ϩimmunofluorescence staining) 29 in the myocardium at 28 days after MI. Figure 6 illustrates that the mice receiving IL-10 showed increased number of GFPϩEPC in the border zone of infarct ( Figure  5A ) associated with enhanced capillary density ( Figure 5B and 5C; PϽ0.05). EPCs were either seen in the vicinity of the existing vascular structures (green and red color) or incorporated into the vascular structures (yellow), suggesting possibilities of both incorporation into vascular structures and paracrine mechanisms aiding in neovascularization. Interestingly, the number of GFPϩEPCs colocalized to CD31ϩvascular structures (yellow) were higher ( Figure  5B and 5D; PϽ0.01) in IL-10 -treated mice. In contrast, both the number and colocalization of GFPϩcells with CD31ϩvascular structures was significantly lower in the myocardium of mice receiving EPCϩSaline.
IL-10 -Induced Upregulation of VEGF Expression in EPCs Is Mediated Through STAT-3
VEGF and STAT3 play an important role in neovascularization during ischemic injury. 30 -32 Our previous studies 29 have shown that IL-10 activates STAT3 and increases VEGF expression in the myocardium after MI. We speculated that EPC-mediated increased neovascularization in IL-10 -treated mice might be through STAT3/VEGF signaling mechanism.
To determine this possibility, we pretreated EPCs with curcurbitacin I (stat3 inhibitor, 1 mol/L) for 1 hour and 10 ng/mL IL-10 versus PBS for an additional 6 hours. VEGF mRNA expression was quantified by real time-PCR analysis ( Figure 6E ). IL-10 treatment significantly increased VEGF expression (PϽ0.01 versus control cells, Figure 6E ). However, inhibition of STAT-3 with curcurbitacin I significantly decreased IL-10-induced VEGF gene expression (PϽ0.01 versus IL-10-treated cells, Figure 6E ), therefore suggesting that IL-10 -induced VEGF in EPCs is mediated through STAT-3 transcription factor.
IL-10 Enhances EPC-Induced LV Functional Recovery
After MI LV function was assessed by echocardiography as described earlier 29 at 7, 14, and 28 days after MI (Figure 7 ) and the associated LV remodeling was examined at 28 days post-MI ( Figure 8 ). The results are available in the online supplement.
Replacement of KO Bone Marrow by WT Bone Marrow Attenuates MI-Induced LV Dysfunction in IL-10 KO Mice
MI was performed after 6 weeks of BMT in IL-10 KO mice (receiving WT marrow; KO-BMT) and WT-mice (receiving IL-10 -deficient marrow; WT-BMT). LV function was assessed by echocardiography at 7, 14, and 28 days, using m-mode tracings (Online Figure VII, A) . The results are available in the online supplement. 
Discussion
Coronary artery disease is a leading cause of morbidity and mortality. There are several repair mechanisms that are now thought to involve circulating EPCs mobilized from the bone marrow and home to sites of ischemic injury. A growing body of evidence in experimental models of cardiac injury suggests that stem cell treatment or transplantation of stem cells remodels and regenerates injured tissue, improves function, and protects tissue from further insult. Indeed, these encouraging results have led to phase I and II clinical trials involving endothelial progenitor cell therapy for a variety of diseases. 14, 15, 33 However, stem cells transplanted in the ischemic myocardium are susceptible to adverse tissue microenvironment such as prolonged inflammation, reduced oxygen sup-ply, and free radical damage, thereby compromising their full therapeutic benefits. Previous studies from our laboratory 28, 29 have shown that IL-10, an anti-inflammatory cytokine, attenuates inflammatory response in the myocardium and improves LV function and remodeling. However, if IL-10mediated inhibition of inflammation in the injured myocardium can also modulate the survival and function of the transplanted EPCs is not known. Therefore, we tested if IL-10 (primarily an anti-inflammatory cytokine) may modulate EPC biology leading to enhanced survival and function after transplantation in an ischemic myocardium and therefore attenuate MI-induced LV dysfunction and remodeling. We report that this indeed is the case. Several lines of evidence support our conclusions: (1) in mice genetically deficient in IL-10 (KO), myocardial ischemia induced mobilization of BM-EPC is impaired; (2) transplantation of WT bone marrow in IL-10 KO mice rescues the BM-EPC mobilization; conversely, replacement of WT marrow with IL-10 KO marrow in WT mice induces impaired EPC mobilization; (3) coadministration of IL-10 enhances the retention and survival of the intramyocardially transplanted EPCs; (4) enhanced EPC survival in the ischemic myocardium is associated with augmentation of EPC-mediated neovascularization and further improvements in the LV function when compared with EPC transplantation alone; and (5) mechanistically, IL-10 effects on EPCs appear to be mediated through SDF-1/CXCR4 and STAT-3/VEGF signaling mechanisms. Endothelial cell proliferation, migration, and sprouting of preexisting blood vessels were considered to be the principal source of new vessel formation. However, evidence suggests that mobilization of EPCs from the bone marrow and their subsequent participation in new vessel formation are essential for repair of injured myocardium. 34 In the present study, flow-cytometry analyses indicated that circulating Sca-1/Flk1 double-positive cell (EPCs) after MI was diminished in IL-10 KO mice as compared with WT mice, suggesting that IL-10 plays a crucial role in mobilization of EPCs. BMT to replace IL-10 KO marrow with WT marrow attenuated these effects, therefore further validating the effect of IL-10 on EPC mobilization. Impaired mobilization in IL-10 KO mice was associated with reduced stromal cell-derived factor 1␣ (SDF-1␣) levels in the border zone of myocardial infarct, suggesting that MI-induced EPC mobilization defect in KO mice might be mediated through SDF-1/CXCR4. The reversal of mobilization defect in KO mice by SDF-1 administration further confirmed this possibility. SDF-1␣ is a chemotactic factor for EPCs in humans; SDF-1␣ induces EPC migration in vitro. 35 SDF-1/CXCR4 signaling axis regulates BM endothelial progenitor cell mobilization, survival, and angiogenesis, as well as several intracellular signaling pathways. 26, 27, 36 Thus, SDF-1␣ and CXCR4 are key regulators of EPC mobilization and recruitment. Previous report has suggested that upregulation of SDF-1␣ in the infarcted myocardium causes massive influx of CXCR4 positive stem cells from the bone marrow. 37 One major finding of the present study is that IL-10 -deficient EPCs showed reduced functional expression of CXCR4 and associated with reduced SDF-1 induced EPC migration in vitro. It has been demonstrated that CXCR4 plays a key role in modulating EPC migration and homing. 38 Figure 6. A and B , EPC-mediated neovascularization in border zone of LV infarct at 28 days after MI. Engraftment of EPC (GFPϩ, green fluorescence) into vascular structures (CD31 staining for capillaries, red fluorescence) is seen as yellow structures. However, some cells are not incorporated (green). Inset is higher magnification of the yellow-boxed area. Bar graph shows quantitative analysis of CD31ϩcapillaries per high-power visual field (hvf) (C) and number of GFPϩcells associated with CD31ϩvasculature (D). Capillary density and EPC engraftment into vascular structures was higher in IL-10 -treated mice (#PϽ0.05). E, Effect of STAT3 on VEGF-A mRNA expression in EPC cells. Curcurbitacin I (Cur, STAT3 inhibitor)-treated cells inhibited IL-10 -induced VEGF-A. mRNA expression normalized to 18S and depicted as fold change versus control (c) untreated cells. *PϽ0.01 versus control cells; #PϽ0.01 versus IL-10 treated cells.
Previous investigation suggested that EPC with reduced functional CXCR4 expression or impaired CXCR4 signaling show decreased migratory capacity. 39 As expected, CXCR4 blocker, AMD3100, abolished the effects of IL-10/SDF-1 on EPC migration. These observations provide clear evidence that the effect of IL-10 on BM-EPC mobilization is mediated through SDF-1/CXCR4 signaling axis.
In the present study, we used Cobalt chloride (CoCl 2 ) to study hypoxia-induced CXCR4 expression and cell death in WT and IL-10 -deficient EPCs. The hypoxic state of EPCs was confirmed by an increase in hypoxia inducible transcription factor 1␣ (HIF1␣). CoCl 2 has been widely used as a hypoxia mimic in both in vivo and in vitro studies and is known to activate hypoxic signaling by stabilizing HIF1␣. 40 However, with varying time and dose of exposure, CoCl 2 can activate a number of other signaling pathways. 41, 42 Increased apoptosis in CoCl 2 treated cells is in agreement with the previous findings that prolonged hypoxia can also induce genes involved in cell death by enhancing the expression of two BH3 domain containing cell death genes, BNip3 and NIX. 41 An interesting finding in the present work is that IL-10 -deficient EPCs showed increased cell death in response to CoCl 2 -induced hypoxia. The signaling mechanism involved in this process is not clear. However, it can be speculated that Heme oxygenase (HO-1) might be playing a significant cytoprotective role in WT-EPCs. 43 HO-1 is highly inducible in response to various stimuli, including oxidative stress, heavy metals, UV radiation, and inflammation.
Previous reports have suggested that prolonged and sustained proinflammatory response in the myocardium could result in adverse outcomes leading to LV dysfunction and remodeling. 23, 44, 45 Our recent studies have shown that IL-10 attenuates MI-induced inflammatory response and associated LV dysfunction and remodeling. 28, 29 A longstanding body of evidence on stem cell therapy describes the challenges in overcoming the susceptibility of transplanted stem cells in a hostile inflammatory and ischemic tissue microenvironment. 46 -48 Previous reports have suggested that prolonged inflammation has been implicated with reduced EPC mobilization, cell death, and functional impairment. 19,20,49 -51 We investigated whether IL-10 enhances EPC survival and incorporation of these EPCs into sites of neovascularization after MI, and whether this enhancement leads to greater preservation of myocardial function and integrity. IL-10 was originally characterized for its ability to inhibit the synthesis of proinflammatory cytokines, but evidence is growing that it directly regulates the growth and survival of noninflammatory cells, as well. 52 The present study reveals that mice receiving IL-10 had a higher number of GFP ϩ EPCs retained in the myocardium as compared with EPCϩsaline group. Interestingly, in EPCϩsaline group, a large number of these GFPϩpositive cells were undergoing apoptosis as compared with the mice that received IL-10. In addition, in vitro experiments show that IL-10 -deficient EPCs show diminished protection against inflammatory stimuli (LPS) or CoCl 2 -mediated hypoxia-induced apoptosis, which is consistent with recent findings that the death of both primary oligodendrocyte progenitor cells and astrocytes was inhibited by IL-10. 53 These studies imply that IL-10 protects transplanted EPC in the ischemic myocardium and thereby increases the numeric availability (retention) of live EPCs, leading to significantly enhanced myocardial repair and LV function. Moreover, evidence exists that not only the cell number but also functional properties of EPC determine the therapeutic success in autologous stem cell transplantation. 15 Recent findings from therapeutic interventions in humans suggest that the microvasculature may be a viable target for cardiovascular therapy. 33 Most compelling, however, are clinical trial data suggesting that protection or restoration of the myocardial microvasculature may provide benefits and that strategies designed to restore microvascular integrity can improve long-term outcomes. 54 In the present study, mice that received IL-10 showed enhanced neovascularization and colocalization of EPCs to CD31ϩvascular structures. These EPCs were either seen in the vicinity of the existing vessels or incorporated into the vascular structures, suggesting possibilities of both engraftment into vascular structures and paracrine mechanisms aiding in neovascularization. In vitro, inhibition of STAT3 with curcurbitacin I in EPCs resulted in reduced IL-10 -mediated VEGF expression. Previous studies have suggested that IL-10 signaling is mediated through STAT3, 55 which regulates a number of key cellular processes including prosurvival and proangiogenic VEGF signaling pathways. 31 However, the requirement of endogenous STAT3 for mediating IL-10 -induced EPC survival and EPCmediated neovascularization signaling has not been explored thus far. Our previous reports have shown that IL-10 increases post-MI neovascularization associated with STAT3 activation and VEGF expression in the myocardium. 29 Our study suggests that IL-10 mediated increased angiogenesis in LV after MI might be a synergy of STAT3 activation in the myocardium/EPC and VEGF expression in the EPC. However, it should be noted that STAT3/VEGF might not be the only signaling mechanisms. A higher HIF1␣ mRNA expression level in WT-EPCs as compared with IL-10 -deficient EPCs (although not significant) suggests this possibility. IL-10 has been shown to modulate other downstream signaling target such as NF-kB and HO-1. 43, 56 These findings along with the EPC survival data suggests that IL-10 protects transplanted EPC in the ischemic myocardium and enhances EPC-mediated neovascularization, after MI.
In animals, the preservation or restoration of microvessels correlates with better LV function after MI, and therapies designed to enhance the microvascular circulation have been shown to preserve cardiac function and integrity. 57 In the present study, LV function assessment revealed that mice receiving EPC along with IL-10 showed much improved LV function than those receiving EPC alone. Improved LV function was associated with reduction in infarct size in IL-10 -treated group. From the above observations, it could be postulated that both increased neoangiogenesis and transdifferentiation of EPCs into cardiomyocyte might have contributed to enhanced EPC-mediated improvement of LV function in IL-10 -treated mice. Furthermore, the reduction in infarction size could be due to formation of new myocytes or due to increased survival of myocytes in the infarcted area due to reduced apoptosis. 58 Recent studies suggest that progenitor cells can transdifferentiate into other lineages. 59 EPCs can contribute to not only vasculogenesis but also myogenesis in the ischemic myocardium in vivo, either through transdifferentiation 60 or through activation of resident cardiac stem cells. 61 However, IL-10 mediated transdifferentiation potential of EPCs in the present study was not explored. Recent studies have also indicated that immunomodulation with anti-inflammatory paracrine factors including IL-10 released by stem cells are important in conferring improved outcome after stem cell therapy. 22, 46, 47 Interestingly, bone marrow mononuclear cells (BM-MNCs) transplanted in the infarcted mouse hearts secreted significant amounts of IL-10 and the cardiac protection was associated with decreased T-lymphocyte accumulation, reactive hypertrophy, and myocardial collagen deposition. 22 Together, these findings provide enticing evidence that IL-10 significantly enhances the survival and angiogenic potential of EPCs, therefore leading to preservation of LV function and integrity in the setting of MI.
Novelty and Significance
What Is Known?
• Recruitment of endothelial progenitor cells (EPC) to the site of injury is fundamental for neovascularization of ischemic tissue. • Chronic proinflammatory response in the myocardium after infarction is associated with cardiomyocyte loss and fibrosis leading to left ventricular dysfunction and adverse remodeling. • Interleukin (IL)-10, an anti-inflammatory cytokine, attenuates inflammatory response in the myocardium and improves left ventricular function and adverse remodeling. • The microenvironment of the ischemic tissue adversely effects EPC survival and function.
What New Information Does This Article Contribute?
• IL-10 enhances survival and function of EPC after transplantation in an ischemic myocardial tissue. • We demonstrate that this action is principally due to the activation of an angiogenic mechanism involving STAT3-dependent induction of the vascular endothelial growth factor. • Deletion of IL-10 in mice reduces EPC mobilization from the bone marrow after myocardial infarction.
Adverse microenvironment of ischemic tissue has a detrimental effect on the survival of mobilized/transplanted EPC, which could compromise their full benefits in cell-based therapy. Prolonged proinflammatory response in the myocardium after myocardial infarction results in cardiomyocyte loss and fibrosis leading to left ventricular dysfunction and adverse remodeling. Therefore, modulation of local tissue proinflammatory response by antiinflammatory factors either released by stem cells or through systemic delivery is important in improving outcome after stem cell therapy. This study demonstrates that myocardial infarction-induced mobilization of bone marrow-EPC is impaired in IL-10 -deficient mice; IL-10 coadministration enhances the retention and survival of the intramyocardially transplanted EPCs, and it augments EPC-mediated neovascularization. Mechanistically, the effects of IL-10 on EPCs are mediated through SDF-1/CXCR4 and STAT-3/VEGF signaling mechanisms. These findings suggest a potential therapeutic role for IL-10 in enhancing the regenerative effects of EPC cell-based therapies by augmenting cell retention and survival on one hand, while modulating EPC biology and EPC-mediated neovascularization on the other. Signaling downstream of IL-10 could be targeted to promote stem cell mobilization, homing and survival for improving the therapeutic efficacy of EPCs.
